Cost –effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma

Immunotherapy, Ahead of Print.

Source: Immunotherapy - June 27, 2022 Category: Allergy & Immunology Authors: Ruizhe Liu Kaifeng Qiu Junyan Wu Yanqing Jiang Peihao Wu Jianxin Pang Source Type: research